Remdesivir, Drugs Monitor, Page 3

(29 April 2020) Remdesivir- Results from interim analysis show 31% faster time to recovery

April 30, 2020

NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19 The interim analysis of results from the trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) suggest… Continue reading "(29 April 2020) Remdesivir- Results from interim analysis show 31% faster time to recovery"

(29 April 2020) Remdesivir- No statistically significant benefits observed for remdesivir

April 29, 2020

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext The results of first randomised, double-blind, placebo controlled clinical trial assessing the effect of intravenous remdesivir in adults admitted to hospital with severe COVID-19 are reported. The… Continue reading "(29 April 2020) Remdesivir- No statistically significant benefits observed for remdesivir"

(27 April 2020) Remdesivir- potently inhibits SARS-CoV-2 replication in human lung cells (EC50 = 0.01 μM)

April 29, 2020

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. https://www.biorxiv.org/content/10.1101/2020.04.27.064279v1 To rapidly evaluate in vivo efficacy, authors have engineered a chimeric SARS- CoV encoding the viral target of Remdesivir, the RNA-dependent… Continue reading "(27 April 2020) Remdesivir- potently inhibits SARS-CoV-2 replication in human lung cells (EC50 = 0.01 μM)"

(13 April 2020) Remdesivir- Late initiation of Remdesivir may be effective

April 23, 2020

Delayed Initiation of Remdesivir in a COVID‐19 Positive Patient https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.2403 A case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical ICU of… Continue reading "(13 April 2020) Remdesivir- Late initiation of Remdesivir may be effective"

(10 April 2020) Remdesivir – 36 out of 53 saw improvements

April 22, 2020

Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2007016 In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require… Continue reading "(10 April 2020) Remdesivir – 36 out of 53 saw improvements"

Tag: Remdesivir

(29 April 2020) Remdesivir- Results from interim analysis show 31% faster time to recovery

(29 April 2020) Remdesivir- No statistically significant benefits observed for remdesivir

(27 April 2020) Remdesivir- potently inhibits SARS-CoV-2 replication in human lung cells (EC50 = 0.01 μM)

(13 April 2020) Remdesivir- Late initiation of Remdesivir may be effective

(10 April 2020) Remdesivir – 36 out of 53 saw improvements